Browsing by Author "Türk M."
Now showing 1 - 9 of 9
Results Per Page
Sort Options
Item Graphene-containing PCL- coated Porous 13-93B3 Bioactive Glass Scaffolds for Bone Regeneration(Institute of Physics Publishing, 2018) Türk M.; Deliormanli A.M.Borate-based 13-93B3 bioactive glass scaffolds were coated with the graphene-containing poly-caprolactone (PCL) solution to prepare electrically conductive composites for biomedical applications. Results revealed that electrical conductivity of the scaffolds increased with increasing concentration of graphene nanoparticles. Significant difference was not observed in hydroxyapatite forming ability of the bare and the graphene-containing scaffolds immersed in simulated body fluid. In vitro cytotoxicity experiments (XTT tests) showed that pre-osteoblastic MC3T3-E1 cell viability percentages of the graphene- containing samples was higher than control group samples after 7 days of incubation. However, a decrease in cell viability rates was obtained after 14 days of incubation for samples coated with PCL containing graphene starting from 3 wt%. Additionally, results obtained in the live-dead assay were consistent with the results of XTT tests. A higher ALP activity was detected in cells cultured on the graphene-containing borate glass scaffolds than those on the bare PCL coated 13-93B3 scaffolds suggesting the presence of graphene nanopowders stimulated an early stage of osteoblastic differentiation. SEM analysis showed that MC3T3-E1 cells exhibited a flat appearance and spread out through the surface in all groups of scaffolds starting from 3 days of incubation. © 2018 IOP Publishing Ltd.Item Response of mouse bone marrow mesenchymal stem cells to graphene-containing grid-like bioactive glass scaffolds produced by robocasting(SAGE Publications Ltd, 2018) Deliormanlı A.M.; Türk M.; Atmaca H.In the study, three-dimensional, grid-like silicate-based bioactive glass scaffolds were manufactured using a robotic deposition technique. Inks were prepared by mixing 13-93 bioactive glass particles in Pluronic® F-127 solution. After deposition, scaffolds were dried at room temperature and sintered at 690°C for 1 h. The surface of the sintered scaffolds was coated with graphene nanopowder (1, 3, 5, 10 wt%) containing poly(ε-caprolactone) solution. The in vitro mineralization ability of the prepared composite scaffolds was investigated in simulated body fluid. The surface of the simulated body fluid-treated scaffolds was analyzed using scanning electron microscopy to investigate the hydroxyapatite formation. Mechanical properties were tested under compression. Results revealed that graphene coating has no detrimental effect on the hydroxyapatite forming ability of the prepared glass scaffolds. On the other hand, it decreased the compression strength of the scaffolds at high graphene concentrations. The prepared grid-like bioactive glass-based composite scaffolds did not show toxic response to bone marrow mesenchymal stem cells. It was shown that stem cells seeded onto the scaffolds attached and proliferated well on the surface. Cells seeded on the scaffolds surface also demonstrated osteogenic differentiation under in vitro conditions in the absence of transforming growth factors. © The Author(s) 2018.Item Investigation the in vitro biological performance of graphene/bioactive glass scaffolds using MC3T3-E1 and ATDC5 cells(Taylor and Francis Ltd., 2018) Deliormanlı A.M.; Türk M.Silicate-based bioactive glass constructs were fabricated by polymer foam replication method for tissue engineering applications. Composites were prepared by coating the surface of bioactive glass scaffolds with poly(ε-caprolactone) involving graphene nanopowders at different concentrations. In vitro bioactivity of the composite constructs was tested in simulated body fluid. Additionally, the response of pre-osteoblastic MC3T3-E1 and chondrogenic ATDC5 cells were investigated under in vitro conditions. Results revealed that a decrease was not observed in acellular bioactivity of the scaffolds. Cell viability experiments showed that graphene involving samples were not cytotoxic to the MC3T3-E1 and ATDC5 cells (except for the samples containing 10 wt% graphene) and cells proliferated well on the scaffolds. Additionally, the pre-osteoblastic cells seeded onto the composite scaffolds differentiated into osteoblasts. The scaffolds prepared in this study may find applications for bone and cartilage tissue engineering in the presence of electric stimulation. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.Item Preparation and characterization of PCL-coated porous hydroxyapatite scaffolds in the presence of MWCNTs and graphene for orthopedic applications(Springer New York LLC, 2019) Deliormanlı A.M.; Türk M.; Atmaca H.Macro-channeled porous hydroxyapatite (HA) scaffolds were fabricated by a polymer foam replication method. Composites were prepared by coating the surface of HA scaffolds with polycaprolactone (PCL) in the presence of graphene nanopowders (in the form of flakes) and multi-walled carbon nanotubes (MWCNTs) at different concentrations. Compression strength of the scaffolds was investigated as a function of additive concentration. Results revealed that the use of PCL coating increased the mechanical strength of HA scaffolds. Besides, addition of graphene or MWCNTs further improved the compression strength of the constructs when they were used at 0.25 wt% and a decrease was observed at higher graphene and MWCNT concentrations. Highest mechanical performance was obtained in composite HA scaffolds involving MWCNTs. In vitro acellular bioactivity experiments revealed that both graphene and MWCNT-incorporated HA scaffolds showed higher bioactivity in simulated body fluid compared to bare scaffolds. However, HA formation ability was more pronounced with MWCNTs compared to graphene nanoflakes where they were possibly acted as an effective nucleation sites to induce the formation of a biomimetic apatite. Additionally, scaffolds prepared in the study were found to be nontoxic to the mouse bone marrow mesenchymal stem cells. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.Item Flow Behavior and Drug Release Study of Injectable Pluronic F-127 Hydrogels containing Bioactive Glass and Carbon-Based Nanopowders(Springer, 2020) Deliormanlı A.M.; Türk M.Injectable biomaterials have gained significant attention in recent years since they can be delivered to the defect sites through minimally-invasive approaches. In this work, thermo-responsive injectable hydrogels containing borate-based bioactive glass particles and carbon-based nanopowders were designed for bone tissue engineering applications. For this purpose, mixtures of Pluronic F127 block-copolymer and 13-93B3 bioactive glass particles with different sizes (2.3 µm, 14 µm, 150 µm) were prepared in aqueous medium and their in situ gelation were investigated through rheological measurements as a function of temperature. Effects of graphene nanopowders and multi-walled carbon nanotubes on the flow behavior of the designed hydrogel system were also investigated. Results revealed that viscosity of the prepared hydrogel system was strongly dependent on the temperature and the bioactive glass particle size. Inclusion of graphene and multi-walled carbon nanotubes in this system caused a further increase in viscosity. All of the hydrogel compositions designed in the study showed shear thinning flow behavior which is a crucial parameter for injectability. Drug release studies showed that the addition of bioactive glass and carbon-based nanoparticles improved the drug release behavior of the prepared hydrogels. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.Item Physical activity and dietary habits in patients with asthma: How is it related to asthma control?(Elsevier Ltd, 2023) Aydın Ö.; Çelebi Sözener Z.; Mungan D.; Özbey Ü.; Balaban S.; Gökmen D.; Zergeroğlu A.M.; Gemicioğlu B.; Yorgancıoğlu A.; Havlucu Y.; Yıldız F.; Argun Barış S.; Çerçi P.; Dursun A.B.; Kalpaklıoğlu F.; Baççıoğlu A.; Atış Naycı S.; Sercan Özgür E.; Kendirlinan R.; Koca Kalkan İ.; Köycü Buhari G.; Yılmaz İ.; Türk M.; Göksel Ö.; Erdinç M.; Damadoğlu E.; Kalyoncu A.F.; Karakaya G.; Ediger D.; Oğuzülgen I.K.; Türktaş H.; Soyyiğit Ş.; Paşaoğlu Karakış G.; Sekibağ Y.; Kızılırmak D.; Dönmez H.; Boğatekin G.; Çakmak M.E.; Kaya S.B.; Günaydın F.E.; Çelik G.Aims: In this study, we aimed to determine the PA and dietary habits of patients with asthma and whether asthma control had a role in these habits. Methods: Adult patients with asthma were included. Three questionnaires were administered to the patients. and daily step counts were recorded for one week. Asthma control level and severe asthma attacks in the previous year were assessed. Results: A total of 277 patients were included. One hundred eighty-two (65.3%) of the patients were overweight/obese. According to FFQ, none of the food groups were comsumed in recommended levels. According to the IPAQ scores, 82.7% of the patients had mild physical activity. The daily step counts and the PA domain of the HLBS-II in obese patients were lower than the nonobese patients (p = 0.001 and p = 0.034,respectively). The rate of obese patients (n = 9; 50%) was higher in the uncontrolled patients. Conclusion: In our study, the majority of patients were physically inactive. Few patients consumed the recommended amount of foods. Being overweight seems to be a significant barrier to the healthy life behaviors. Although these behaviours do not seem to have an effect on asthma controlling this study, further prospective placebo-controlled studies are needed. © 2022 Elsevier LtdItem Asthma-chronic obstructive pulmonary disease overlap: Results from a national-multicenter study; [Astım KOAH overlap: Ulusal çok merkezli bir çalışma sonuçları](Ankara University, 2024) Çelik G.E.; Aydin Ö.; Şen E.; Demir T.; Gemicioğlu B.; Kiyan E.; Mungan D.; Kivilcim Oğuzülgen İ.; Polatli M.; Göksel Ö.; Sayiner A.; Yildirim N.; Yildiz F.; Yorgancioğlu A.; Elhan A.H.; Yildiz Ö.; Başyiğit İ.; Börekçi Ş.; Havlucu Y.; Okumuş G.; Türk M.; Saryal S.Introduction: Patients with asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) have a greater disease burden than those with COPD or asthma alone. In this study, it was aimed to determine the prevalence, risk factors, and clinical features of ACO because there are limited national data in Türkiye. Materials and Methods: The study was conducted in a cross-sectional design in nine tertiary-care hospitals. The patients followed with a diagnosis of asthma or COPD for at least one year were enrolled in the study. The frequency of ACO and the characteristics of the patients were evaluated in the asthma and COPD groups. Results: The study included 408 subjects (F/M= 205/203, mean age= 56.24 ± 11.85 years). The overall prevalence of ACO in both groups was 20.8% (n= 85). The frequency was higher in the COPD group than in the asthma group (n= 55; 33.3% vs. n= 22; 9.8%), respectively (p= 0.001). Patients with ACO had similarities to patients with COPD in terms of advanced age, sex, smoking, exposure to biomass during childhood, being born in rural areas, and radio-logic features. Characteristics such as a history of childhood asthma and allergic rhinitis, presence of chronic sinusitis, NSAID hypersensitivity, atopy, and high eosinophil counts were similar to those of patients with asthma (p< 0.001). The annual decline in FEV1 was more prominent in the ACO group (mean=-250 mL) than in the asthma (mean change=-60 mL) and COPD (mean change=-230 mL) groups (p= 0.003). Conclusion: This study showed that ACO was common among patients with asthma and COPD in tertiary care clinics in our country. ACO should be considered in patients with asthma and COPD who exhibit the abovementioned symptoms. © 2024 by Tuberculosis and Thorax.Item Socioeconomic status has direct impact on asthma control: Turkish adult asthma registry(John Wiley and Sons Inc, 2025) Arslan B.; Türk M.; Hayme S.; Aydin Ö.; Gokmen D.; Buhari G.K.; Sozener Z.C.; Gemicioglu B.; Bulut I.; Beyaz S.; Orcen C.; Ozdemir S.K.; Keren M.; Damadoglu E.; Yakut T.; Kalpaklioglu A.F.; Baccioglu A.; Yalim S.A.; Yilmaz I.; Kalkan I.K.; Ozgun Niksarlioglu E.Y.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayci S.; Tepetam F.M.; Gelincik A.A.; Dirol H.; Goksel O.; Karaoglanoglu S.; Erkekol F.O.; Isik S.R.; Yildiz F.; Yavuz Y.; Karadogan D.; Bozkurt N.; Seker U.; Oguzulgen I.K.; Basyigit I.; Baris S.A.; Ucar E.Y.; Erdogan T.; Polatli M.; Ediger D.; Gunaydin F.E.; Pur L.; Katran Z.Y.; Sekibag Y.; Aykac E.F.; Mungan D.; Gul O.; Cengiz A.; Akkurt B.; Ozden S.; Demir S.; Unal D.; Aslan A.F.; Can A.; Gumusburun R.; Bogatekin G.; Akten H.S.; Inan S.; Erdinc M.; Ogus A.C.; Kavas M.; Yulug D.P.; Cakmak M.E.; Kaya S.B.; Alpagat G.; Ozgur E.S.; Uzun O.; Gulen S.T.; Pekbak G.; Kizilirmak D.; Havlucu Y.; Donmez H.; Cetin G.P.; Soyyigit S.; Kara B.Y.; Karakis G.P.; Dursun A.B.; Kendirlinan R.; Ozturk A.B.; Sevinc C.; Simsek G.O.; Abadoglu O.; Cerci P.; Yucel T.; Yorulmaz I.; Tezcaner Z.C.; Tatar E.C.; Suslu A.E.; Ozer S.; Dursun E.; Yorgancioglu A.; Celik G.E.; Uysal M.A.Background: Asthma is one of the most common causes of chronic respiratory disease, and countries with low socioeconomic status have both a high prevalence of asthma and asthma-related death. Objective: In this study, we aimed to determine socioeconomic levels of asthmatic patients according to a national database and investigate the effects of social markers on disease control in our region. Methods: This is an analysis of data from 2053 adult asthma patients from a multicentre chart study in Turkey. Socioeconomic status (SES) data were collected from questionnaires and this form was sent to the patients via e-mail. Parameters related to social status and poor disease control were analyzed. Results: Illiteracy (OR:2.687 [95% CI: 1.235–5.848]; p = 0.013) and lower household income (OR:1,76 [95% CI: 1.002–3.09]; p = 0.049) were found as independent risk factors for hospitalization in the multivariate logistic regression analysis. Therewithal, being aged between 40 and 60 (OR: 1.435 [95% CI: 1.074–1.917]; p = 0.015), illiteracy (OR: 2.188 [95% CI: 1.262–3.795]; p = 0.005) and being employed (OR: 1.466 [95% CI: 1.085–1.847]; p = 0.011) were considered as independent risk factors for systemic corticosteroid use at least 3 days within last 1 year. Conclusion: As a result of our national database, education level, household income and working status briefly socioeconomic status have impacts on asthma control. Identification of social markers in asthma and better recognition of risk factors based on the population gives us clues to provide better asthma control in the future. © 2025 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.Item Trends in prescribing montelukast in patients with asthma in real-life: Results from the Turkish adult asthma registry(Exon Publications, 2025) Beyaz Ş.; Erdinç M.; Hayme S.; Aslan A.F.; Aydın Ö.; Gökmen D.; Buhari G.K.; Sözener Z.Ç.; Gemicioğlu B.; Bulut İ.; Örçen C.; Özdemir S.K.; Keren M.; Damadoğlu E.; Yakut T.; Kalpaklıoğlu A.F.; Baccıoğlu A.; Yalım S.A.; Yılmaz İ.; Kalkan İ.K.; Uysal M.A.; Niksarlıoğlu E.Y.Ö.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayc S.; Tepetam F.M.; Gelincik A.A.; Dirol H.; Göksel Ö.; Karaoğlanoğlu S.; Erkekol F.Ö.; Isık S.R.; Yıldız F.; Yavuz Y.; Karadoğan D.; Bozkurt N.; Şeker Ü.; Oğuzülgen İ.K.; Başyiğit İ.; Barış S.A.; Uçar E.Y.; Erdoğan T.; Polatlı M.; Ediger D.; Günaydın F.E.; Türk M.; Pür L.; Katran Z.Y.; Sekibağ Y.; Aykaç E.F.; Mungan D.; Gül Ö.; Cengiz A.; Akkurt B.; Özden Ş.; Demir S.; Ünal D.; Can A.; Gümüşburun R.; Boğatekin G.; Akten H.S.; İnan S.; Öğüş A.C.; Kavas M.; Yuluğ D.P.; Çakmak M.E.; Kaya S.B.; Alpagat G.; Özgür E.S.; Uzun O.; Gülen Ş.T.; Pekbak G.; Kızılırmak D.; Havlucu Y.; Dönmez H.; Arslan B.; Çetin G.P.; Soyyiğit Ş.; Kara B.Y.; Karakış G.P.; Dursun A.B.; Kendirlinan R.; Öztürk A.B.; Sevinç C.; Şimşek G.Ö.; Abadoğlu Ö.; Çerçi P.; Yücel T.; Yorulmaz İ.; Tezcaner Z.Ç.; Tatar E.Ç.; Süslü A.E.; Özer S.; Dursun E.; Yorgancıoğlu A.; Çelik G.E.Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This registry-based study evaluated the use of montelukast in adult asthma patients, examining demographic and disease characteristics, asthma control status, asthma phenotypes, presence of atopy, and treatment regimens. Among 2053 patients analyzed, 61.76% (n = 1268; mean age: 46.2 ± 14.3 years), predominantly females (~76%), received montelukast. Montelukast users showed higher rates of allergic rhinitis (P < 0.001), hyper-sensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) (P = 0.008), and chronic rhinosi-nusitis (P = 0.008). Montelukast group also had higher atopy and total IgE levels and tended to be more eosinophilic. Montelukast was commonly preferred in allergic, eosinophilic, NSAID-exacerbated respiratory disease, and severe asthma phenotypes (P < 0.001). Patients receiving Steps 4 and 5 treatments are more likely to be prescribed montelukast (P < 0.001). Montelukast usage was higher among patients with uncontrolled asthma [ACT< 20 (OR:1.29, 95%CI:1.052–1.582, P = 0.014)]. In addition, logistic regression analyses identified the main factors associated with increased montelukast use as; female gender (OR:1.33, 95%CI:1.041–1.713, P = 0.02), presence of atopy (OR:1.46, 95%CI:1.157–1.864, P = 0.002), comorbid allergic rhinitis (OR:2.12, 95%CI:1.679–2.293, P < 0.001), and severe asthma (OR:2.18, 95%CI:1.712–2.784, P < 0.001). These findings reveal that montelukast use is prevalent among asthma patients, particularly in females, middle-aged adults, and those with comorbid allergic rhinitis, uncontrolled asthma, or specific asthma phenotypes, underscoring the factors that influence its prescription in asthma management. © 2025 Codon Publications.